Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial

LESSONS LEARNED: Administration of autologous invariant natural killer T (iNKT) cells was safe and well‐tolerated in patients with hepatocellular carcinoma (Barcelona Clinic Liver Cancer stage B/C). Expanded iNKT cells produced T‐helper 1–like responses with possible antitumor activity. No severe ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yao, Guo, Jia, Bao, Xuli, Xiong, Fang, Ma, Yanpin, Tan, Bingqin, Yu, Lele, Zhao, Yong, Lu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571770/
https://www.ncbi.nlm.nih.gov/pubmed/34255901
http://dx.doi.org/10.1002/onco.13899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571770/
https://www.ncbi.nlm.nih.gov/pubmed/34255901
http://dx.doi.org/10.1002/onco.13899

Ejemplares similares